Please login to the form below

Not currently logged in
Email:
Password:

Betmiga

This page shows the latest Betmiga news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

Vibegron was licensed from Merck &Co/MSD in 2017 and is billed as an improved version of Astellas’ Myrbetriq/Betmiga (mirabegron), which was the first beta3-adrenergic agonist to reach the

Latest news

  • Eylea's UK launch earns Bayer PMEA success Eylea's UK launch earns Bayer PMEA success

    strategy. Other companies recognised in the category included Astellas, which was highly commended for its launch of overactive bladder treatment Betmiga, while Astellas and Shire were both finalists.

  • Germany’s IQWiG denies Astellas’ incontinence drug Germany’s IQWiG denies Astellas’ incontinence drug

    IQWiG determined that Betmiga had a superior side effect profile to tolterodine as there were fewer incidences of dry mouth. ... The decision is in contrast to the positive guidance from the UK's National Institute for Health and Care Excellence (NICE),

  • NICE recommends Astellas' Betmiga for overactive bladder NICE recommends Astellas' Betmiga for overactive bladder

    Vesicare is due to lose patent protection in 2018, however, and Betmiga extends Astellas' reach in the therapy area, while also producing fewer side effects than Vesicare. ... Betmiga was approved by the European Commission in January 2013, adding to its

  • European approval for Astellas' first-in-class bladder drug Betmiga

    Will compete with Pfizer's Detrol and Astellas' own Vesicare. The European Commission has approved Astellas' overactive bladder treatment Betmiga (mirabegron). ... However, the company will have to be careful with how it positions Betmiga to avoid

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    However, we have also just launched Betmiga in the UK, developed in-house, which sits in a similar prescribing OAB space, but with a novel mode of action.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics